Skip to content

The impact of different timings of sugammadex administration in the PACU on the postoperative muscle relaxation recovery and awakening quality of patients undergoing laparoscopic surgery: A prospective randomized controlled

The impact of different timings of sugammadex administration in the PACU on the postoperative muscle relaxation recovery and awakening quality of patients undergoing laparoscopic surgery: A prospective randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600127408
Enrollment
Unknown
Registered
2026-06-30
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incidence of residual muscle relaxation after surgery

Interventions

Preventive administration group:Administer the medication as soon as the patient is admitted to the recovery room
Rescue medication group:Administer the drug when body movement occurs or eyes are open for the first time

Sponsors

Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Patients scheduled to undergo laparoscopic surgery under general anesthesia (including cholecystectomy, appendectomy, hysterectomy, and prostatectomy); 2.ASA classification levels I - III; 3.Age 18 - 85 years old; 4.Body Mass Index (BMI) 18 - 40 kg/m^2; 5.Fully informed consent and signing of the informed consent form; 6.2h<operation time<4h;

Exclusion criteria

Exclusion criteria: 1.Refusal to participate in this study; 2.Communication disorders, inability to cooperate with the researchers, such as language comprehension disorders, mental illnesses, epilepsy, history of alcohol or other drug abuse, or myasthenia gravis; 3.Individuals who have a confirmed or suspected history of alcohol, analgesic drug, or other drug abuse and addiction; 4.Those with severely abnormal liver and kidney functions (severe liver dysfunction: one of ALT, conjugated bilirubin, AST, ALP, or total bilirubin is more than twice the upper limit of normal; severe kidney dysfunction: Cr clearance rate 177 umol/L); 5.Those who are allergic to Sugammadex or neostigmine; 6.Those who cannot obtain satisfactory ultrasound images or who are unable to perform ultrasound operations.

Design outcomes

Primary

MeasureTime frame
Extubation time;

Secondary

MeasureTime frame
QoR-15 scale score 24 hours after the operation;The mean value of DE-DB of the diaphragm during deep breathing 30 minutes after extubation;The time when TOFr>0.9;The mean value of DE-DB of the diaphragm during deep breathing 10 minutes after extubation;The time it takes to achieve an Aldrete score of >=9;Postoperative adverse events;

Countries

China

Contacts

Public ContactCheng Yuan

Affiliated hangzhou first people's hospital, zhejiang university school of medicine

13806522883@163.com+86 571 56007240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026